Breast Cancer Clinical Trial
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
Summary
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).
Eligibility Criteria
Inclusion Criteria:
Women status post segmental mastectomy
If unilateral, pT1-2 breast cancer excised with negative margins
If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised with negative margins.
Clinically N0 or pN0 or sentinel node negative
Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).
Exclusion Criteria:
Previous radiation therapy to the ipsilateral breast.
90 days from last surgery, unless s/p adjuvant chemotherapy
60 days from last chemotherapy
Male breast cancer
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
New York New York, 10007, United States More Info
Principal Investigator
New York New York, 11215, United States More Info
Principal Investigator
New York New York, 11355, United States More Info
Principal Investigator
How clear is this clinincal trial information?